Dragon Tamer: New Models Needed To Capture China Opportunities
Executive Summary
As China enacts reforms to open up to novel drugs, companies must rapidly change their approaches and adopt new business models to seize the window of opportunity, industry insiders tell a recent partnering event in the country.
You may also be interested in...
Can Alibaba Use Artificial Intelligence To Solve China Health Issues?
When China’s e-commerce giant Alibaba flexes its muscles, this time in personalized healthcare using artificial intelligence, everyone takes note.
Authorization Holder Scheme To Shake Up China R&D, Drug Production
When a roomful of attendees at the annual ChinaTrials meeting, held Nov. 4 in Beijing, voted that a planned marketing authorization holder (MAH) system would be the single development likely to have the most impact on the pharma industry, few predicted that the scheme would come true just hours later.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.